Almirall has acquired the rights to Veltin and Altabax, from Stiefel, a GSK company, in exchange for distribution rights to Toctino and an undisclosed cash payment more


Valeant Pharmaceuticals International has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle more